How to buy DermTech stock | $11.72

DermTech, Inc is a diagnostics & research business based in the US. DermTech shares (DMTK) are listed on the NASDAQ and all prices are listed in US Dollars. DermTech employs 60 staff and has a trailing 12-month revenue of around USD$5.4 million.

How to buy shares in DermTech

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for DermTech. Find the stock by name or ticker symbol: DMTK. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DermTech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$11.72, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of DermTech, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of DermTech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

DermTech share price

Use our graph to track the performance of DMTK stocks over time.

DermTech shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$11.72
52-week range	USD$8.69 - USD$27.4196
50-day moving average	USD$13.8355
200-day moving average	USD$12.4851
Wall St. target price	USD$21.75
PE ratio	58.8462
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.08

Buy DermTech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy DermTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of DermTech, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DermTech price performance over time

Historical closes compared with the close of $11.72 from 2020-12-09

1 week (2021-01-07)	-69.42%
1 month (2020-12-17)	-18.04%
3 months (2020-10-16)	4.74%
6 months (2020-07-16)	4.74%

1 year (2020-01-16)	15.70%
2 years (2019-01-14)	14.12%
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Is DermTech under- or over-valued?

Valuing DermTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DermTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DermTech's P/E ratio

DermTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, DermTech shares trade at around 59x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DermTech financials

Revenue TTM	USD$5.4 million
Gross profit TTM	USD$60,000
Return on assets TTM	-47.74%
Return on equity TTM	-86.93%
Profit margin	0%
Book value	$1.579
Market capitalisation	USD$486 million

TTM: trailing 12 months

Shorting DermTech shares

There are currently 954,707 DermTech shares held short by investors – that's known as DermTech's "short interest". This figure is 45.2% up from 657,702 last month.

There are a few different ways that this level of interest in shorting DermTech shares can be evaluated.

DermTech's "short interest ratio" (SIR)

DermTech's "short interest ratio" (SIR) is the quantity of DermTech shares currently shorted divided by the average quantity of DermTech shares traded daily (recently around 237489.30348259). DermTech's SIR currently stands at 4.02. In other words for every 100,000 DermTech shares traded daily on the market, roughly 4020 shares are currently held short.

However DermTech's short interest can also be evaluated against the total number of DermTech shares, or, against the total number of tradable DermTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DermTech's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 DermTech shares in existence, roughly 50 shares are currently held short) or 0.074% of the tradable shares (for every 100,000 tradable DermTech shares, roughly 74 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DermTech.

Find out more about how you can short DermTech stock.

DermTech share dividends

We're not expecting DermTech to pay a dividend over the next 12 months.

Have DermTech's shares ever split?

DermTech's shares were split on a 1:2 basis on 30 August 2019. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DermTech shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for DermTech shares which in turn could have impacted DermTech's share price.

DermTech overview

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Frequently asked questions

• What percentage of DermTech is owned by insiders or institutions?

  Currently 23.571% of DermTech shares are held by insiders and 57.648% by institutions.

• How many people work for DermTech?

  Latest data suggests 60 work at DermTech.

• When does the fiscal year end for DermTech?

  DermTech's fiscal year ends in December.

• Where is DermTech based?

  DermTech's address is: 11099 North Torrey Pines Road, La Jolla, CA, United States, 92037

• What is DermTech's ISIN number?

  DermTech's international securities identification number is: US24984K1051

• What is DermTech's CUSIP number?

  DermTech's Committee on Uniform Securities Identification Procedures number is: 24984K105